29-year Study shows Long-Term Benefits to Mammography
Mammographic screening sharply lowers the risk of breast cancer death over the long-term, according to a study published online June 28 in the journal Radiology.
Mammographic screening sharply lowers the risk of breast cancer death over the long-term, according to a study published online June 28 in the journal Radiology.
The study, which followed 133,056 women aged 40-74 for 29 years, divided women – all from two Swedish counties – into groups who received mammography and a control group who did not. The screening period lasted seven years, with women from 40-49 being screened every two years and those 50- 74 every 33 months.
For every 414 to 519 women undergoing mammogram screenings, one breast cancer death was prevented, found the team led by author Stephen W. Duffy, MSc, of Queen Mary University of London.
"In this study, we've continued to monitor women for nearly three decades and we've found that the longer we look, the more lives are saved," Duffy said in a statement.
The study represents a statistical counterpoint to the U.S. Preventative Task Force’s controversial 2009 recommendation to eliminate routine breast-cancer screening for women in their 40s. Breast Cancer is the second most lethal of cancers among women, behind only lung cancer.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
